Welcome to our dedicated page for Vaxcyte SEC filings (Ticker: PCVX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vaxcyte, Inc. (Nasdaq: PCVX) SEC filings page on Stock Titan provides access to the company’s official disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage vaccine innovation company developing broad-spectrum conjugate and novel protein vaccines against bacterial diseases, Vaxcyte uses its SEC reports to communicate financial results, material agreements and key milestones for its pneumococcal conjugate vaccine (PCV) franchise and broader pipeline.
Investors can review Form 8-K current reports in which Vaxcyte furnishes press releases on quarterly financial results, clinical and regulatory updates, and significant contracts. For example, recent 8-K filings reference earnings announcements and a master services agreement with Patheon Manufacturing Services LLC, part of Thermo Fisher Scientific, under which Patheon will formulate, fill, package, label, test, manufacture and supply drug product for Vaxcyte at a facility in Greenville, North Carolina. These filings outline key commercial supply arrangements, binding minimum order commitments, term length and termination provisions.
In addition to 8-Ks, users can expect to find Vaxcyte’s periodic reports such as Form 10-Q and Form 10-K (when available), which typically include detailed discussions of the company’s PCV programs (VAX-31, VAX-24 and VAX-XL), early-stage candidates like VAX-A1 and VAX-GI, use of the XpressCF cell-free protein synthesis platform, risk factors and liquidity information. These documents help explain how Vaxcyte is prioritizing resources for its PCV franchise, its capital position and its manufacturing investments.
Stock Titan’s interface is designed to surface new Vaxcyte filings in near real time as they appear on EDGAR and to pair them with AI-generated summaries that highlight the sections most relevant to shareholders, such as clinical program updates, material agreements, and changes in strategy. Users can also look for Form 4 and related ownership filings to monitor insider transactions when they are reported. Together, these filings offer a structured view of how Vaxcyte is advancing its pneumococcal and bacterial vaccine programs from both a scientific and corporate perspective.
Vaxcyte, Inc. SVP, Finance & CAO Elvia Cowan exercised stock options and sold shares in a routine, partially pre-planned transaction. Cowan exercised options for 2,500 shares of common stock at $25.92 per share and then sold 2,500 shares at an average price of $58.5927 per share.
The filing also shows 495 shares of common stock were surrendered to Vaxcyte to cover tax withholding obligations upon RSU vesting, which is described as a non-market disposition. After these transactions, Cowan directly holds 30,867 shares of Vaxcyte common stock. The sale was carried out under a Rule 10b5-1 trading plan adopted on December 8, 2025, indicating it was pre-scheduled rather than opportunistic.
Vaxcyte, Inc. chief operating officer Jim Wassil reported recent stock transactions. On March 9, 2026, 975 shares of common stock were surrendered to the company to cover tax withholding obligations upon RSU vesting, which is an automatic, non-market disposition.
On March 10, 2026, he completed two open-market sales totaling 7,395 shares of common stock at weighted-average prices of $58.316 and $59.160. These sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 9, 2025. After these transactions, he directly holds 166,818 shares of Vaxcyte common stock, indicating that he retains a substantial equity position.
PCVX notice of proposed sale of 2,500 common shares via exercise of stock options on 03/11/2026. The filing lists shares outstanding of 143,920,361 as of 03/11/2026. It also records a prior sale of 11,623 shares on 12/23/2025 for $556,971.85.
PCVX filed a Form 144 notice to sell Common shares tied to RSU vestings. The filing lists multiple RSU vesting events and quantities, including 03/02/2026 — 1,803 shares; 02/28/2026 — 1,602 shares; 03/07/2026 — 1,740 shares; and 02/28/2025 — 2,250 shares. The entries are identified as RSU Vest and show the issuer as the source.
Vaxcyte, Inc. reported insider equity transactions by Elvia Cowan, its SVP, Finance & CAO. On February 26, 2026, Cowan received a grant of stock options for 17,855 shares and a separate award of 10,681 restricted stock units, each RSU representing one share of common stock.
The RSUs vest as to one quarter of the shares on September 7, 2026, then one eighth every six months, subject to continued service. The new option vests as to one forty-eighth of the shares on March 26, 2026, and monthly thereafter, also subject to continued service.
On the same date, Cowan exercised 7,716 stock options at $25.92 per share, receiving the same number of common shares. On February 28 and March 2, 2026, a total of 569 shares were surrendered at $61.98 per share to cover tax withholding on vested RSUs. After these transactions, Cowan directly owned 31,362 common shares.
Vaxcyte, Inc. reported that President and CFO Andrew Guggenhime received equity awards and had shares withheld to cover taxes. On February 26, 2026, he was granted 44,864 shares of common stock in the form of RSUs and 74,993 stock options. On February 28 and March 2, 2026, a total of 1,907 shares of common stock were surrendered to the company to satisfy tax withholding on RSU vesting. He also reports indirect ownership of 61,850 shares held by ALG 2025 GRAT HOLDINGS LLC, a grantor retained annuity trust for which he is annuitant and trustee.
Vaxcyte, Inc. director and chief executive officer Grant Pickering reported equity compensation grants and related tax-withholding share dispositions. On February 26, 2026, he received a grant of 105,110 shares of Common Stock and a stock option for 175,698 shares, both at a stated price of $0.00 per share, as awards. The option vests as to 1/48 of the shares on March 26, 2026, then 1/48 monthly thereafter, subject to continued service. The common stock award represents RSUs that vest 1/4 on September 7, 2026 and 1/8 every six months after, also contingent on continued service. To cover tax withholding from RSU vesting, he surrendered 2,531 shares on March 2, 2026 and 2,863 shares on February 28, 2026 at $61.98 per share. After these transactions, he directly owned just over 500,000 Common Stock shares, with additional indirect holdings reported through trusts for the benefit of his son and daughter.
Vaxcyte, Inc. reported insider equity activity by Chief Technical Ops Officer Harpreet S. Dhaliwal. On February 26, 2026, Dhaliwal received grants of 53,409 shares of common stock and 46,424 stock options, both at a reported price of $0.00 per share as awards. The common stock grant represents restricted stock units that vest over time starting September 7, 2026. On February 28 and March 2, 2026, a total of 757 shares of common stock were disposed of at $61.98 per share to cover tax withholding obligations upon RSU vesting. After these transactions, Dhaliwal directly held 76,580 shares of common stock.
Vaxcyte, Inc. chief operating officer Jim Wassil reported equity compensation activity and related tax withholdings. He received 32,045 restricted stock units at a grant price of $0.00 per share, plus an additional 5,102 RSUs at $61.74 per share. He was also granted a stock option for 53,566 shares at a $0.00 exercise price, vesting in monthly installments beginning March 26, 2026.
To cover tax obligations from RSU vesting, shares of common stock were surrendered back to the company: 1,900 shares at $61.74 per share, 898 shares at $61.98 per share, and 1,009 shares at $61.98 per share. After these transactions, he directly owned 175,188 shares of common stock.
Vaxcyte, Inc. entered a new at-the-market stock offering program allowing it to sell up to $500,000,000 of common stock through Leerink Partners as placement agent under an existing shelf registration on Form S-3.
The shares may be sold from time to time on Nasdaq or other permitted markets, with Leerink Partners earning up to 3.00% of gross proceeds. Vaxcyte simultaneously terminated its prior Open Market Sale Agreement with Jefferies, under which it had previously sold approximately $270.3 million of common stock.